Ralaniten (developmental code name EPI-002) is an N-terminal domain antiandrogen which was never marketed.

[1] It is a derivative of bisphenol A[2] and one of the four stereoisomers of EPI-001.

[1] A prodrug of ralaniten, ralaniten acetate (EPI-506), was under development for the treatment of prostate cancer.

[3] This antineoplastic or immunomodulatory drug article is a stub.

You can help Wikipedia by expanding it.This drug article relating to the genito-urinary system is a stub.